CE1226 is developed by CSL Behring.

What development phase is CE1226 in?

CE1226 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

CE1226

CSL Behring · FDA-approved active Biologic Quality 4/100

At a glance

Generic name	CE1226
Also known as	Human alpha1-proteinase inhibitor, Respreeza, Zemaira
Sponsor	CSL Behring
Modality	Biologic
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CE1226 CI brief — competitive landscape report
CE1226 updates RSS · CI watch RSS
CSL Behring portfolio CI